Biotech Stocks Rally Led by Merck on Promising Cancer Vaccine Data

Key Facts

In a move reflecting renewed optimism in medical breakthroughs, the biotechnology sector witnessed a broad rally driven by positive clinical data. Merck shares jumped 12.4% following the announcement of successful results for a cancer vaccine developed in collaboration with Moderna, triggering significant institutional and retail buying. According to reports, this development pushed several biotech stocks to reach their highest levels since the post-pandemic era.

The rally extended across major biopharma players, with Eli Lilly shares rising 4.0% and Amgen gaining 3.7%, signaling broad sector participation. Per market data, LLY closed at 1273.36 and JNJ at 272.49 on August 19, 2026, while AMGN stood at 425.28 and ABBV at 258.92 as of the August 18, 2026 close.

Traders are now watching for price consolidation following the surge, with MRK at 135.18 (close August 18, 2026). While the upcoming economic calendar shows no direct catalysts for the pharma sector in the immediate window, market participants will monitor if LLY can maintain its momentum after testing a day high of 1292.50 during the latest session.